Study of a new drug for advanced solid tumors and lymphomas
Part of Cancer clinical trials.
This study tests a new drug called XZ120 for people with advanced cancers, including breast cancer and a type of lymphoma. The goal is to see if it is safe and effective, and to find the right dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have advanced cancer that has not responded to standard treatment or a type of breast cancer or lymphoma that can be treated with standard therapy.
- You must be generally healthy with a performance status of 0 or 1, which means you can do most daily activities.
- Your heart function must be adequate, with an ejection fraction of 50% or higher.
- Your blood counts and liver and kidney function must be within acceptable levels.
- You must not have had certain previous treatments, like high doses of anthracyclines, or other cancers within the last 5 years (except for treated early-stage cervical or skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests XZB-0004 in adults with solid cancers to check safety and how the body responds to the drug. It may help doctors learn whether this treatment could be useful for certain tumor types, including non-small cell lung cancer.
This trial tests a new drug, XB628, alone or together with another drug called zanzalintinib, in people whose advanced solid tumor has continued to grow after at least one prior treatment. The goal is to see if these combinations can shrink tumors or slow their growth.
This trial tests a new medication, HLX51, which may help the immune system fight cancer. It is for people with advanced solid tumors or lymphoma who have tried standard treatments without success or cannot receive them.
This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.